Dec 16 (Reuters) - Reviva Pharmaceuticals Holdings, Inc.
:
* REVIVA ANNOUNCES POSITIVE PRELIMINARY TOPLINE DATA FOR THE LONG-TERM OPEN LABEL EXTENSION PORTION OF THE PHASE 3 RECOVER STUDY EVALUATING BRILAROXAZINE IN SCHIZOPHRENIA
* FULL DATA SET FROM OPEN-LABEL EXTENSION (OLE) OF RECOVER EXPECTED IN Q1 2025
* ALL THREE DOSES OF BRILAROXAZINE (15 MG, 30 MG AND 50 MG) TESTED EFFICACIOUS & GENERALLY WELL-TOLERATED
Source text: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。